This Startup Raised $38 Million To Fill One Of The Biggest Gaps In Drug Discovery
Vivodyne CEO Andrei Georgescu (L) and Chief Commercial Officer Susan Billings (R). VivoDyne Only about 10% of drugs in development ever make it to market. That number has remained largely unchanged since the early 1990s, despite milestone advances in science — genomics, automated systems for conducting experiments and artificial intelligence. One big reason: lab research …